



ASX Release

14 November 2019

Zelda Therapeutics cannabis formulations to be supplied to the CARE NSW clinical trial for symptom control in cancer patients

- **Zelda to commercially supply an oil-based cannabis medicine formulation for the CARE NSW Clinical Trial involving up to 600 patients**
- **The CARE NSW Clinical Trial will be assessing safety, tolerability and efficacy of different cannabis medicine formulations to provide symptom relief in advanced cancer patients**
- **Zelda-supplied products meet TGA requirements for cannabis medicines**
- **Agreement will generate revenues and raise awareness of Zelda-branded products**

Zelda Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) (“Zelda”) is pleased to announce it has entered into an agreement with the National Health and Medical Research Council (NHMRC)-funded Australian Centre for Clinical Cannabinoid Research Excellence (ACRE), based at the University of Newcastle, to commercially supply a cannabis oil formulation, where prescribed, for participants in the Cannabinoids for Symptom Control in Advanced Cancer, An Open Label Prospective Clinical Trial in NSW (CARE NSW).

The CARE NSW Clinical Trial is seeking to enrol up to 600 advanced cancer patients who will be prescribed a product selected from a range of cannabis medicines for symptom management. Zelda is one of several suppliers selected to supply investigation product for the trial under a commercial contract.

The agreement does not guarantee suppliers with a minimum or maximum volume of the investigational product to be purchased nor the frequency of required supply to the CARE NSW trial.

Zelda’s Managing Director, Dr Richard Hopkins commented *“We’re delighted for the opportunity to supply investigational product in the CARE NSW trial. The focus on studying cannabis as a strategy to potentially alleviate symptoms in advanced cancer patients is very much aligned to our strategic interests in this area.*

The commercial supply agreement also represents a significant milestone for our shareholders, as it is expected to generate the Company's first revenues from Zelda-branded TGA-TG093 compliant products. This is an important step towards commercialisation of Zelda's own clinically validated products for sleep, chronic pain and anxiety, which the Zelda is expected to launch from 2020.

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company is undertaking:

- A **human clinical trial program** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- A **pre-clinical research program** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The company conducts this work in partnership with world-leading researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelda has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access HAPA pharm's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.

On 9 October 2019, Zelda announced plans to merge with Ilera Therapeutics (Ilera), a privately held medicinal cannabis and cannabinoid science company based in the United States, which will be renamed Zelira Therapeutics Limited (Zelira). Subject to approval from Zelda shareholders, and all conditions of sale being met, Zelda is proposing to acquire 100% of Ilera Therapeutics through an all-scrip transaction.

The merger will create a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets. The merger will bring together a world-class portfolio of revenue generating medicines and products undergoing clinical development that are expected to enter the market from 2020.

About Ilera Therapeutics LLC

Ilera Therapeutics LLC is a US-based company established by a team of experienced executives in the global bio-pharmaceutical sector. The Company is based in Pennsylvania and engaged in the development and formulation of proprietary, branded cannabis products and cannabinoids science focused on targeted medical and other indications.

The Team developed two proprietary formulations (HOPE™) already launched and generating revenues in Pennsylvania, has lab capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products. The company also has a partnership with Ethicann for the development of a proprietary product, CAN-001, which is being developed for the treatment of chemotherapy-induced nausea and vomiting (CINV), which occurs in approximately 80% of the new 23.6 million cases of cancer annually worldwide.

Address

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com
ACN 103 782 378

Tickers

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Contacts

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications

Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Ordinary Shares

758,841,934

Options

83,596,667